Genolution

Genolution ROIC

The Return on Invested Capital (ROIC) of Genolution (225220.KQ) as of Oct 22, 2026 is -17.02 %. In the previous year, Return on Invested Capital (ROIC) was -6.54 % — a change of 160.25% (lower).

ROIC

-17.02 %

YoY

160.25%

Last updated:

Return on Invested Capital (ROIC) of Genolution is 2025 -17.02 % . Return on Invested Capital (ROIC) of Genolution was 2024 -6.54 % . It decreases by 160.25% lower compared to the previous year.

The Genolution ROIC history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

ROIC
Date
ROIC
Jan 1, 2018
28.20 KRW
Jan 1, 2019
-4.64 KRW
Jan 1, 2020
47.17 KRW
Jan 1, 2021
41.84 KRW
Jan 1, 2022
13.30 KRW
Jan 1, 2023
-4.98 KRW
Jan 1, 2024
-6.54 KRW
Jan 1, 2025
-17.02 KRW
The Genolution ROIC history
YEARROICYoY
-17.02 %+160.25%
-6.54 %+31.41%
-4.98 %-137.41%
13.30 %-68.20%
41.84 %-11.30%
47.17 %-1,117.48%
-4.64 %-116.44%
28.20 %+95.53%
14.42 %+460.77%
2.57 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Genolution Stock analysis

What does Genolution do? Genolution Inc develops automated nucleic acid extraction devices, nucleic acid extraction reagents, and molecular diagnostic products. The company also offers ribonucleic acid interference services. Its products are distributed domestically and internationally, serving customers in the biotechnology and healthcare sectors. The firm generates revenue through the sale of these products and services to research institutions, laboratories, and healthcare providers. The company's core offerings include nucleic acid extractors, reagents, and diagnostic products, which are used in molecular biology and medical diagnostics. Genolution Inc targets biotech firms, hospitals, and research facilities as key buyers of its technology. Its domestic market presence complements its international distribution channels. Genolution Inc's business model relies on selling its automated extraction devices and reagents to customers requiring efficient nucleic acid processing solutions. The company's molecular diagnostic products cater to healthcare applications, while its ribonucleic acid interference services support advanced research needs. Revenue streams are derived from both product sales and service contracts within the biotechnology industry. Genolution is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Genolution stock

Return on Invested Capital (ROIC) of Genolution is -17.02 % in 2025.

Return on Invested Capital (ROIC) of Genolution changed from -6.54 % to -17.02 %, representing a 160.25% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Return on Invested Capital (ROIC) Genolution since 2006 – with annual values, charts, and detailed analysis.

ROIC measures how effectively a company uses its invested capital to generate profits. A ROIC above the cost of capital creates shareholder value.

ROIC = NOPAT / Invested Capital

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Invested Capital (ROIC)'s Genolution with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Invested Capital (ROIC)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Invested Capital (ROIC).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Genolution

All Key Metrics — Genolution